Clinical Trials Logo
  1. Home
  2. Cardiac Failure
  3. NCT02932566

The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction — PIROUETTE  

Cardiac Failure Clinical Trial

Official title:
A Randomised, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction (PIROUETTE)

Clinical Trial Summary

This randomised, double-blind, placebo-controlled, phase 2 study aims to evaluate the efficacy and safety of the anti-fibrotic drug pirfenidone in the treatment of patients with heart failure and preserved left ventricular ejection fraction (HFpEF). Participants will be randomised to receive either pirfenidone or placebo, for a period of 12 months.

Clinical Trial Description

Myocardial fibrosis is a key pathological mechanism in HFpEF. Pirfenidone is an anti-fibrotic medication licensed for the treatment of idiopathic lung fibrosis, for which it reduces lung function decline, improves progression free survival and reduces all cause mortality. In pre-clinical models, pirfenidone attenuates profibrotic pathways and is associated with regression of myocardial fibrosis. Previous studies in HFpEF populations using anti-fibrotic medications, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor blockers and aldosterone antagonists have shown some benefit in reaching secondary end-points but do not reduce mortality. HFpEF is the final result of a number of specific underlying pathological mechanisms, and targeted treatment of these mechanisms has been cited as the future approach to further clinical trials. The investigators aim to select a population of HFpEF patients with high levels of interstitial myocardial fibrosis as measured on cardiac MRI (CMR), and randomise participants to receive pirfenidone or placebo. The primary outcome is to detect a significant reduction in myocardial fibrosis as measured on CMR after 12 months of intervention. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02932566
Study type Interventional
Source Manchester University NHS Foundation Trust
Contact
Status Completed
Phase Phase 2
Start date March 2, 2017
Completion date April 29, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT03799133 - Safety and Efficacy of the Gastric Reactance (XL) in Patients Post-operated of Elective Cardiac Surgery N/A
Not yet recruiting NCT04538469 - Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
Terminated NCT02205411 - Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation N/A
Completed NCT02524574 - Tomography Positron Emission Assessment of the Impact of Cardiac Rehabilitation on Coronary Endothelial Function in Cardiac Failure N/A
Active, not recruiting NCT03841084 - Blend to Limit Oxygen in ECMO: A Randomised Controlled Registry Trial Phase 2
Terminated NCT02459054 - Syncardia 50cc TAH-t as a Bridge to Transplant N/A
Terminated NCT02859636 - Pronostic Value of Endothelial Dysfunction in Heart Failure N/A
Completed NCT04599816 - Levosimendan Administration in Pulmonary Hypertension N/A
Recruiting NCT05761639 - Physical Exercise and Telephone Follow-up Mediated by Telerehabilitation N/A
Not yet recruiting NCT04696523 - Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage Phase 2
Completed NCT03357731 - A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function Phase 2
Completed NCT02331264 - Cardiac Assessment of Patients With Hip Implants N/A
Terminated NCT01921829 - Protocolized Diuretic Strategy in Cardiorenal Failure Phase 4
Completed NCT06197256 - Cardiac Dysfunction in Critically Ill Covid-19 Patients
Recruiting NCT03197792 - Perioperative Portal Vein Pulsatility as a Postoperative Prognostic Indicator in Pulmonary Endarterectomy N/A
Completed NCT03515980 - An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function Phase 1
Completed NCT03212898 - Pharmacist Interventions in Rural Elderly Warfarin Patients N/A
Completed NCT03243604 - cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study
Completed NCT06330103 - Efficacy of AI EF Screening by Using Smartphone Application Recorded PLAX View Cardiac Ultrasound Video Clips N/A
Completed NCT02660385 - Insomnia Self-Management in Heart Failure N/A